CCNE1 and PLK1 mediates resistance to palbociclib in HR+/HER2- metastatic breast cancer.

Angel L Guerrero-Zotano Stefania Belli Christoph C Zielinski Juan Miguel Gil-Gil Antonio Fernandez-Serra Manuel Ruiz Borrego Eva Ciruelos Gil Javier Pascual Montserrat Muñoz Begoña Bermejo Mireia Margelí Antonio Antón-Torres Laura Murillo Bella Nisenbaum Yuan Liu Jesus Herranz Daniel Fernandez-Garcia Rosalía Caballero Jose Antonio Lopez-Guerrero Roberto Bianco Luigi Formisano Nicholas C Turner Miguel Martin

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

We confirm the association of non-luminal subtype and CCNE1 with resistance to CDK4/6i+ET in HR+ MBC. High levels of PLK1 mRNA identify patients with poor response to palbociclib, suggesting PLK1 could also play a role in the setting of resistance to CDK4/6i.

Keyphrases

metastatic breast cancer
cell cycle
cell proliferation
binding protein